Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database

The potent oral inhibitor of BCL2, venetoclax (VEN), used to treat adults with chronic lymphocytic leukaemia, has been approved in US for the treatment of naïve patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy and recently in Europe, too. However, the drug has been used fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzo, Lucia, Vetro, Calogero, Brancati, Serena, Longo, Laura, Vitale, Daniela Cristina, Romano, Giovanni Luca, Mauro, Elisa, Fiumara, Paolo Fabio, Maugeri, Cinzia, Parisi, Marina Silvia, Dulcamare, Ilaria, Garibaldi, Bruno, Duminuco, Andrea, Palumbo, Giuseppe Alberto, Di Raimondo, Francesco, Drago, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660092/
https://www.ncbi.nlm.nih.gov/pubmed/34899303
http://dx.doi.org/10.3389/fphar.2021.748766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660092/
https://www.ncbi.nlm.nih.gov/pubmed/34899303
http://dx.doi.org/10.3389/fphar.2021.748766

Ejemplares similares